<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31120172</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>05</Month>
        <Day>29</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1742-4658</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>286</Volume>
            <Issue>18</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Sep</Month>
            </PubDate>
          </JournalIssue>
          <Title>The FEBS journal</Title>
          <ISOAbbreviation>FEBS J</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Role of the mTOR signalling pathway in salivary gland development.</ArticleTitle>
        <Pagination>
          <StartPage>3701</StartPage>
          <EndPage>3717</EndPage>
          <MedlinePgn>3701-3717</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/febs.14937</ELocationID>
        <Abstract>
          <AbstractText>Development of the salivary gland is characterized by extensive branching morphogenesis. Although various molecules have been implicated in salivary gland development, the role of the mammalian target of rapamycin (mTOR) signalling pathway, including both mTOR complexes 1 and 2 (mTORC1 and 2), in salivary gland development is unknown. Here, we examined protein expression levels related to the mTOR signalling pathway using an ex vivo submandibular salivary gland (SMG) organ culture. We showed that branching buds in the salivary glands were substantially decreased and phosphorylation of mTORC1 signalling pathway related proteins (mTOR, p70 ribosomal protein S6 kinase 1 and eukaryotic initiation factor 4E-binding protein 1) was inhibited by rapamycin (an mTOR inhibitor). In addition, AKT, which is an upstream protein kinase of mTORC1 and is downstream of mTORC2, is inhibited by LY294002 (a phosphatidylinositol 3-kinase inhibitor), but not by rapamycin. Moreover, rapamycin-treated ICR neonatal mice exhibited a reduction in both body weight and salivary glands compared with vehicle-treated neonatal mice. The present data indicate that the mTOR signalling pathway, including both mTORC1 and mTORC2, plays a critical role in salivary gland development both in ex vivo SMG organ culture and ICR neonatal mice in vivo.</AbstractText>
          <CopyrightInformation>© 2019 Federation of European Biochemical Societies.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Sakai</LastName>
            <ForeName>Manabu</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Laboratory, Osaka University Dental Hospital, Suita, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fukumoto</LastName>
            <ForeName>Moe</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cell Biology, National Cerebral and Cardiovascular Center Research Institute, Suita, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ikai</LastName>
            <ForeName>Kazuki</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oral-facial Disorders, Osaka University Graduate School of Dentistry, Suita, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ono Minagi</LastName>
            <ForeName>Hitomi</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oral-facial Disorders, Osaka University Graduate School of Dentistry, Suita, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Inagaki</LastName>
            <ForeName>Shinobu</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Child Development &amp; Molecular Brain Science, Osaka University United Graduate School of Child Development, Suita, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kogo</LastName>
            <ForeName>Mikihiko</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>First Department of Oral and Maxillofacial Surgery, Osaka University Graduate School of Dentistry, Suita, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sakai</LastName>
            <ForeName>Takayoshi</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oral-facial Disorders, Osaka University Graduate School of Dentistry, Suita, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>Challenging Exploratory Research (15K15737)</GrantID>
            <Agency>Japan Society for the Promotion of Science</Agency>
            <Country>International</Country>
          </Grant>
          <Grant>
            <GrantID>Scientific Research (A) (15H02575)</GrantID>
            <Agency>Japan Society for the Promotion of Science</Agency>
            <Country>International</Country>
          </Grant>
          <Grant>
            <GrantID>Young Scientists (B) (17K17244)</GrantID>
            <Agency>Japan Society for the Promotion of Science</Agency>
            <Country>International</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>06</Month>
          <Day>03</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>FEBS J</MedlineTA>
        <NlmUniqueID>101229646</NlmUniqueID>
        <ISSNLinking>1742-464X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002867">Chromones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009025">Morpholines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>31M2U1DVID</RegistryNumber>
          <NameOfSubstance UI="C085911">2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.1</RegistryNumber>
          <NameOfSubstance UI="C546843">mTOR protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D000076222">Mechanistic Target of Rapamycin Complex 1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D000076225">Mechanistic Target of Rapamycin Complex 2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>W36ZG6FT64</RegistryNumber>
          <NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002867" MajorTopicYN="N">Chromones</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004622" MajorTopicYN="N">Embryo, Mammalian</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047108" MajorTopicYN="N">Embryonic Development</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000076222" MajorTopicYN="N">Mechanistic Target of Rapamycin Complex 1</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000076225" MajorTopicYN="N">Mechanistic Target of Rapamycin Complex 2</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009024" MajorTopicYN="N">Morphogenesis</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009025" MajorTopicYN="N">Morpholines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009924" MajorTopicYN="N">Organ Culture Techniques</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012469" MajorTopicYN="N">Salivary Glands</DescriptorName>
          <QualifierName UI="Q000254" MajorTopicYN="N">growth &amp; development</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020123" MajorTopicYN="N">Sirolimus</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013363" MajorTopicYN="N">Submandibular Gland</DescriptorName>
          <QualifierName UI="Q000254" MajorTopicYN="N">growth &amp; development</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">development</Keyword>
        <Keyword MajorTopicYN="Y">differentiation</Keyword>
        <Keyword MajorTopicYN="Y">organ culture</Keyword>
        <Keyword MajorTopicYN="Y">salivary gland</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2018</Year>
          <Month>12</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2019</Year>
          <Month>3</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>5</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31120172</ArticleId>
        <ArticleId IdType="doi">10.1111/febs.14937</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>References</Title>
        <Reference>
          <Citation>Albert V &amp; Hall MN (2015) mTOR signaling in cellular and organismal energetics. Curr Opin Cell Biol 33, 55-66.</Citation>
        </Reference>
        <Reference>
          <Citation>Laplante M &amp; Sabatini DM (2012) mTOR signaling in growth control and disease. Cell 149, 274-293.</Citation>
        </Reference>
        <Reference>
          <Citation>Saxton RA &amp; Sabatini DM (2017) mTOR signaling in growth, metabolism, and disease. Cell 169, 361-371.</Citation>
        </Reference>
        <Reference>
          <Citation>Foster KG &amp; Fingar DC (2010) Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony. J Biol Chem 285, 14071-14077.</Citation>
        </Reference>
        <Reference>
          <Citation>Sarbassov DD, Guertin DA, Ali SM &amp; Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098-1101.</Citation>
        </Reference>
        <Reference>
          <Citation>Hay N &amp; Sonenberg N (2004) Upstream and downstream of mTOR. Genes Dev 18, 1926-1945.</Citation>
        </Reference>
        <Reference>
          <Citation>Garami A, Zwartkruis FJT, Nobukuni T, Joaquin M, Roccio M, Stocker H, Kozma SC, Hafen E, Bos JL &amp; Thomas G (2003) Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol Cell 11, 1457-1466.</Citation>
        </Reference>
        <Reference>
          <Citation>Chauvin C, Koka V, Nouschi A, Mieulet V, Hoareau-Aveilla C, Dreazen A, Cagnard N, Carpentier W, Kiss T, Meyuhas O, et al. (2014) Ribosomal protein S6 kinase activity controls the ribosome biogenesis transcriptional program. Oncogene 33, 474-483.</Citation>
        </Reference>
        <Reference>
          <Citation>Gingras AC, Gygi SP, Raught B, Polakiewicz RD, Abraham RT, Hoekstra MF, Aebersold R &amp; Sonenberg N (1999) Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes Dev 13, 1422-1437.</Citation>
        </Reference>
        <Reference>
          <Citation>Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, Hall A &amp; Hall MN (2004) Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 6, 1122-1128.</Citation>
        </Reference>
        <Reference>
          <Citation>Lamouille S, Connolly E, Smyth JW, Akhurst RJ &amp; Derynck R (2012) TGF-beta-induced activation of mTOR complex 2 drives epithelial-mesenchymal transition and cell invasion. J Cell Sci 125, 1259-1273.</Citation>
        </Reference>
        <Reference>
          <Citation>Holz MK, Ballif BA, Gygi SP &amp; Blenis J (2005) mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell 123, 569-580.</Citation>
        </Reference>
        <Reference>
          <Citation>Huang JX &amp; Manning BD (2009) A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem Soc Trans 37, 217-222.</Citation>
        </Reference>
        <Reference>
          <Citation>Thoreen CC &amp; Sabatini DM (2009) Rapamycin inhibits mTORC1, but not completely. Autophagy 5, 725-726.</Citation>
        </Reference>
        <Reference>
          <Citation>Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL &amp; Sabatini DM (2006) Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 22, 159-168.</Citation>
        </Reference>
        <Reference>
          <Citation>Guertin DA &amp; Sabatini DM (2005) An expanding role for mTOR in cancer. Trends Mol Med 11, 353-361.</Citation>
        </Reference>
        <Reference>
          <Citation>Guertin DA &amp; Sabatini DM (2007) Defining the role of mTOR in cancer. Cancer Cell 12, 9-22.</Citation>
        </Reference>
        <Reference>
          <Citation>Davies JA (2002) Do different branching epithelia use a conserved developmental mechanism? BioEssays 24, 937-948.</Citation>
        </Reference>
        <Reference>
          <Citation>Metzger RJ &amp; Krasnow MA (1999) Genetic control of branching morphogenesis. Science 284, 1635-1639.</Citation>
        </Reference>
        <Reference>
          <Citation>Sakai T, Larsen M &amp; Yamada KM (2003) Fibronectin requirement in branching morphogenesis. Nature 423, 876-881.</Citation>
        </Reference>
        <Reference>
          <Citation>Sakai T &amp; Onodera T (2008) Embryonic organ culture. Curr Protoc Cell Biol Chapter 19, Unit 19.8.</Citation>
        </Reference>
        <Reference>
          <Citation>Sakai M, Matsushita T, Hoshino R, Ono H, Ikai K &amp; Sakai T (2017) Identification of the protective mechanisms of Lactoferrin in the irradiated salivary gland. Sci Rep 7, 9753.</Citation>
        </Reference>
        <Reference>
          <Citation>Onodera T, Sakai T, Hsu JC, Matsumoto K, Chiorini JA &amp; Yamada KM (2010) Btbd7 regulates epithelial cell dynamics and branching morphogenesis. Science 329, 562-565.</Citation>
        </Reference>
        <Reference>
          <Citation>Steinberg Z, Myers C, Heim VM, Lathrop CA, Rebustini IT, Stewart JS, Larsen M &amp; Hoffman MP (2005) FGFR2b signaling regulates ex vivo submandibular gland epithelial cell proliferation and branching morphogenesis. Development 132, 1223-1234.</Citation>
        </Reference>
        <Reference>
          <Citation>Larsen M, Wei C &amp; Yamada KM (2006) Cell and fibronectin dynamics during branching morphogenesis. J Cell Sci. 119, 3376-3384.</Citation>
        </Reference>
        <Reference>
          <Citation>Knox SM, Lombaert IM, Haddox CL, Abrams SR, Cotrim A, Wilson AJ &amp; Hoffman MP (2013) Parasympathetic stimulation improves epithelial organ regeneration. Nat Commun 4, 1494.</Citation>
        </Reference>
        <Reference>
          <Citation>Larsen M, Hoffman MP, Sakai T, Neibaur JC, Mitchell JM &amp; Yamada KM (2003) Role of PI 3-kinase and PIP3 in submandibular gland branching morphogenesis. Dev Biol 255, 178-191.</Citation>
        </Reference>
        <Reference>
          <Citation>Phyu SM, Tseng CC, Fleming IN &amp; Smith TA (2016) Probing the PI3K/Akt/mTor pathway using. Sci Rep 6, 36544.</Citation>
        </Reference>
        <Reference>
          <Citation>Gao X &amp; Han H (2018) Jolkinolide B inhibits glycolysis by downregulating hexokinase 2 expression through inactivating the Akt/mTOR pathway in non-small cell lung cancer cells. J Cell Biochem 119, 4967-4974.</Citation>
        </Reference>
        <Reference>
          <Citation>Tang MJ, Cai Y, Tsai SJ, Wang YK &amp; Dressler GR (2002) Ureteric bud outgrowth in response to RET activation is mediated by phosphatidylinositol 3-kinase. Dev Biol 243, 128-36.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang J, Ito T, Udaka N, Okudela K, Yazawa T &amp; Kitamura H (2005) PI3K-AKT pathway mediates growth and survival signals during development of fetal mouse lung. Tissue Cell 37, 25-35.</Citation>
        </Reference>
        <Reference>
          <Citation>Land SC, Scott CL &amp; Walker D (2014) mTOR signalling, embryogenesis and the control of lung development. Semin Cell Dev Biol 36, 68-78.</Citation>
        </Reference>
        <Reference>
          <Citation>Dennis MD, Coleman CS, Berg A, Jefferson LS &amp; Kimball SR (2014) REDD1 enhances protein phosphatase 2A-mediated dephosphorylation of Akt to repress mTORC1 signaling. Sci Signal 7, ra68.</Citation>
        </Reference>
        <Reference>
          <Citation>Oudart JB, Doué M, Vautrin A, Brassart B, Sellier C, Dupont-Deshorgue A, Monboisse JC, Maquart FX, Brassart-Pasco S &amp; Ramont L (2016) The anti-tumor NC1 domain of collagen XIX inhibits the FAK/ PI3K/Akt/mTOR signaling pathway through αvβ3 integrin interaction. Oncotarget 7, 1516-1528.</Citation>
        </Reference>
        <Reference>
          <Citation>Han EK, Leverson JD, McGonigal T, Shah OJ, Woods KW, Hunter T, Giranda VL &amp; Luo Y (2007) Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition. Oncogene 26, 5655-5661.</Citation>
        </Reference>
        <Reference>
          <Citation>Hoffman MP, Kidder BL, Steinberg ZL, Lakhani S, Ho S, Kleinman HK &amp; Larsen M (2002) Gene expression profiles of mouse submandibular gland development: FGFR1 regulates branching morphogenesis in vitro through BMP- and FGF-dependent mechanisms. Development 129, 5767-5778.</Citation>
        </Reference>
        <Reference>
          <Citation>Koyama N, Hayashi T, Ohno K, Siu L, Gresik EW &amp; Kashimata M (2008) Signaling pathways activated by epidermal growth factor receptor or fibroblast growth factor receptor differentially regulate branching morphogenesis in fetal mouse submandibular glands. Dev Growth Differ 50, 565-576.</Citation>
        </Reference>
        <Reference>
          <Citation>Yamada A, Futagi M, Fukumoto E, Saito K, Yoshizaki K, Ishikawa M, Arakaki M, Hino R, Sugawara Y, Naruse M, et al. (2016) Connexin 43 is necessary for salivary gland branching morphogenesis and FGF10-induced ERK1/2 phosphorylation. J Biol Chem. 291, 904-912.</Citation>
        </Reference>
        <Reference>
          <Citation>Trueb B, Amann R &amp; Gerber SD (2013) Role of FGFRL1 and other FGF signaling proteins in early kidney development. Cell Mol Life Sci 70, 2505-2518.</Citation>
        </Reference>
        <Reference>
          <Citation>Qiao J, Uzzo R, Obara-Ishihara T, Degenstein L, Fuchs E &amp; Herzlinger D (1999) FGF-7 modulates ureteric bud growth and nephron number in the developing kidney. Development 126, 547-554.</Citation>
        </Reference>
        <Reference>
          <Citation>Ohuchi H, Hori Y, Yamasaki M, Harada H, Sekine K, Kato S &amp; Itoh N (2000) FGF10 acts as a major ligand for FGF receptor 2 IIIb in mouse multi-organ development. Biochem Biophys Res Commun 277, 643-649.</Citation>
        </Reference>
        <Reference>
          <Citation>Volckaert T &amp; De Langhe SP (2015) Wnt and FGF mediated epithelial-mesenchymal crosstalk during lung development. Dev Dyn 244, 342-366.</Citation>
        </Reference>
        <Reference>
          <Citation>Hashemolhosseini S, Nagamine Y, Morley SJ, Desrivières S, Mercep L &amp; Ferrari S (1998) Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J Biol Chem 273, 14424-14429.</Citation>
        </Reference>
        <Reference>
          <Citation>Grewe M, Gansauge F, Schmid RM, Adler G &amp; Seufferlein T (1999) Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells. Cancer Res 59, 3581-3587.</Citation>
        </Reference>
        <Reference>
          <Citation>Averous J, Fonseca BD &amp; Proud CG (2008) Regulation of cyclin D1 expression by mTORC1 signaling requires eukaryotic initiation factor 4E-binding protein 1. Oncogene 27, 1106-1113.</Citation>
        </Reference>
        <Reference>
          <Citation>Yang Q, Chen LS, Neelapu SS, Miranda RN, Medeiros LJ &amp; Gandhi V (2012) Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma. Blood 120, 3491-3500.</Citation>
        </Reference>
        <Reference>
          <Citation>Law M, Forrester E, Chytil A, Corsino P, Green G, Davis B, Rowe T &amp; Law B (2006) Rapamycin disrupts cyclin/cyclin-dependent kinase/p21/proliferating cell nuclear antigen complexes and cyclin D1 reverses rapamycin action by stabilizing these complexes. Cancer Res 66, 1070-1080.</Citation>
        </Reference>
        <Reference>
          <Citation>Tee AR, Sampson JR, Pal DK &amp; Bateman JM (2016) The role of mTOR signalling in neurogenesis, insights from tuberous sclerosis complex. Semin Cell Dev Biol 52, 12-20.</Citation>
        </Reference>
        <Reference>
          <Citation>Hennig M, Fiedler S, Jux C, Thierfelder L &amp; Drenckhahn JD (2017) Prenatal mechanistic target of rapamycin complex 1 (m TORC1) inhibition by rapamycin treatment of pregnant mice causes intrauterine growth restriction and alters postnatal cardiac growth, morphology, and function. J Am Heart Assoc 6, e005506.</Citation>
        </Reference>
        <Reference>
          <Citation>Tsai PT, Greene-Colozzi E, Goto J, Anderl S, Kwiatkowski DJ &amp; Sahin M (2013) Prenatal rapamycin results in early and late behavioral abnormalities in wildtype C57BL/6 mice. Behav Genet 43, 51-59.</Citation>
        </Reference>
        <Reference>
          <Citation>Kashimata M, Sayeed S, Ka A, Onetti-Muda A, Sakagami H, Faraggiana T &amp; Gresik EW (2000) The ERK-1/2 signaling pathway is involved in the stimulation of branching morphogenesis of fetal mouse submandibular glands by EGF. Dev Biol 220, 183-196.</Citation>
        </Reference>
        <Reference>
          <Citation>Liu P, Gan W, Chin YR, Ogura K, Guo J, Zhang J, Wang B, Blenis J, Cantley LC, Toker A, et al. (2015) PtdIns(3,4,5)P3-dependent activation of the mTORC2 kinase complex. Cancer Discov 5, 1194-209.</Citation>
        </Reference>
        <Reference>
          <Citation>Yang G, Murashige DS, Humphrey SJ &amp; James DE (2015) A positive feedback loop between Akt and mTORC2 via SIN1 phosphorylation. Cell Rep 12, 937-943.</Citation>
        </Reference>
        <Reference>
          <Citation>Zinzalla V, Stracka D, Oppliger W &amp; Hall MN (2011) Activation of mTORC2 by association with the ribosome. Cell 144, 757-768.</Citation>
        </Reference>
        <Reference>
          <Citation>Bhaskar PT &amp; Hay N (2007) The two TORCs and Akt. Dev Cell 12, 487-502.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhu W &amp; Nelson CM (2012) PI3K signaling in the regulation of branching morphogenesis. Biosystems 109, 403-411.</Citation>
        </Reference>
        <Reference>
          <Citation>Ghosh S, Lau H, Simons BW, Powell JD, Meyers DJ, De Marzo AM, Berman DM &amp; Lotan TL (2011) PI3K/mTOR signaling regulates prostatic branching morphogenesis. Dev Biol 360, 329-342.</Citation>
        </Reference>
        <Reference>
          <Citation>Manning BD (2004) Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J Cell Biol 167, 399-403.</Citation>
        </Reference>
        <Reference>
          <Citation>Manning BD, Logsdon MN, Lipovsky AI, Abbott D, Kwiatkowski DJ &amp; Cantley LC (2005) Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. Genes Dev 19, 1773-1778.</Citation>
        </Reference>
        <Reference>
          <Citation>Kato H &amp; Perl A (2014) Mechanistic target of rapamycin complex 1 expands Th17 and IL-4+ CD4-CD8- double-negative T cells and contracts regulatory T cells in systemic lupus erythematosus. J Immunol 192, 4134-4144.</Citation>
        </Reference>
        <Reference>
          <Citation>Kato H &amp; Perl A (2018) Blockade of Treg Cell differentiation and function by the interleukin-21-mechanistic target of rapamycin axis via suppression of autophagy in patients with systemic lupus erythematosus. Arthritis Rheumatol 70, 427-438.</Citation>
        </Reference>
        <Reference>
          <Citation>Hartwell LH &amp; Kastan MB (1994) Cell-cycle control and cancer. Science 266, 1821-1828.</Citation>
        </Reference>
        <Reference>
          <Citation>Muise-Helmericks RC, Grimes HL, Bellacosa A, Malstrom SE, Tsichlis PN &amp; Rosen N (1998) Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway. J Biol Chem. 273, 29864-29872.</Citation>
        </Reference>
        <Reference>
          <Citation>Liang J &amp; Slingerland JM (2003) Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2, 339-345.</Citation>
        </Reference>
        <Reference>
          <Citation>Moldovan GL, Pfander B &amp; Jentsch S (2007) PCNA, the maestro of the replication fork. Cell 129, 665-679.</Citation>
        </Reference>
        <Reference>
          <Citation>Diamanti S, Nikitakis N, Rassidakis G, Doulis I &amp; Sklavounou A (2016) Immunohistochemical evaluation of the mTOR pathway in intra-oral minor salivary gland neoplasms. Oral Dis. 22, 620-629.</Citation>
        </Reference>
        <Reference>
          <Citation>Clauditz TS, Gontarewicz A, Bokemeyer C, Sauter G, Knecht R, Münscher A &amp; Wilczak W (2013) Abundant expression of mTOR kinase in salivary gland tumors - potentials as therapy target? J Oral Pathol Med 42, 769-773.</Citation>
        </Reference>
        <Reference>
          <Citation>Sisto M, Lisi S &amp; Ribatti D (2018) The role of the epithelial-to-mesenchymal transition (EMT) in diseases of the salivary glands. Histochem Cell Biol 150, 133-147.</Citation>
        </Reference>
        <Reference>
          <Citation>Ettl T, Schwarz-Furlan S, Haubner F, Müller S, Zenk J, Gosau M, Reichert TE &amp; Zeitler K (2012) The PI3K/AKT/mTOR signalling pathway is active in salivary gland cancer and implies different functions and prognoses depending on cell localisation. Oral Oncol. 48, 822-830.</Citation>
        </Reference>
        <Reference>
          <Citation>Lai ZW, Kelly R, Winans T, Marchena I, Shadakshari A, Yu J, Dawood M, Garcia R, Tily H, Francis L, et al. (2018) Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial. Lancet 391, 1186-1196.</Citation>
        </Reference>
        <Reference>
          <Citation>Savage N (2017) New tricks from old dogs join the fight against ageing. Nature 552, S57-S59.</Citation>
        </Reference>
        <Reference>
          <Citation>Li J, Kim SG &amp; Blenis J (2014) Rapamycin: one drug, many effects. Cell Metab 19, 373-379.</Citation>
        </Reference>
        <Reference>
          <Citation>Perl A (2015) mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging. Ann N Y Acad Sci 1346, 33-44.</Citation>
        </Reference>
        <Reference>
          <Citation>Bozorgi SS, Proctor GB &amp; Carpenter GH (2014) Rapamycin delays salivary gland atrophy following ductal ligation. Cell Death Dis 5, e1146.</Citation>
        </Reference>
        <Reference>
          <Citation>Blagosklonny MV (2017) From rapalogs to anti-aging formula. Oncotarget 8, 35492-35507.</Citation>
        </Reference>
        <Reference>
          <Citation>Blagosklonny MV (2018) Rapamycin, proliferation and geroconversion to senescence. Cell Cycle 17, 2655-2665.</Citation>
        </Reference>
        <Reference>
          <Citation>Blagosklonny MV (2018) Does rapamycin slow down time? Oncotarget 9, 30210-30212.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
